Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

Here’s a closer look at the top pharmaceutical companies that have earned favorable rankings from Wolfe Research analysts. Johnson & Johnson takes the top spot with growth primarily driven by new ...

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

BlackRock Health Sciences Trust is a Buy for income investors, offering an 8% yield, NAV discount, and resilient healthcare ...

Warren Buffett's recommended investment strategy would have been profitable 100% of the time throughout history.

Novo Nordisk finds itself navigating significant operational and market headwinds. The company is intensely focused on maintaining its leadership in the obes ...